Published in Eur J Pharmacol on January 30, 2006
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther (2004) 2.27
Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res (2004) 2.05
Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity. J Pharmacol Exp Ther (2009) 1.13
Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation (2003) 1.11
Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation (2003) 1.11
Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther (2002) 1.10
Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology (2009) 1.08
Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol (2005) 1.04
In vivo activity of a phospholipase C inhibitor, 1-(6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione (U73122), in acute and chronic inflammatory reactions. J Pharmacol Exp Ther (2004) 1.03
Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis (2002) 1.03
Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation (2005) 1.01
Quantitation of the contractile response mediated by two receptors: M2 and M3 muscarinic receptor-mediated contractions of human gastroesophageal smooth muscle. J Pharmacol Exp Ther (2009) 0.97
Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction. Am J Physiol Regul Integr Comp Physiol (2002) 0.97
Midazolam enhances the analgesic properties of dexmedetomidine in the rat. Vet Anaesth Analg (2010) 0.96
A multiplexed proteomics approach to differentiate neurite outgrowth patterns. J Neurosci Methods (2006) 0.96
Intra-VTA CART 55-102 reduces the locomotor effect of systemic cocaine in rats: an isobolographic analysis. Neuropeptides (2007) 0.94
Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice. J Pharmacol Exp Ther (2008) 0.92
Sirolimus-eluting stents: a review of experimental and clinical findings. Z Kardiol (2002) 0.92
A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide. J Pharmacol Exp Ther (2006) 0.92
Combination strategies for pain management. Expert Opin Pharmacother (2003) 0.91
Inhibition of GSK3 attenuates dopamine D1 receptor agonist-induced hyperactivity in mice. Brain Res Bull (2010) 0.90
Update on sirolimus drug-eluting stents. Curr Pharm Des (2004) 0.89
The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J Pain (2010) 0.89
The use of occupation isoboles for analysis of a response mediated by two receptors: M2 and M3 muscarinic receptor subtype-induced mouse stomach contractions. J Pharmacol Exp Ther (2008) 0.88
Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia. Pain (2007) 0.88
Resveratrol in combination with other dietary polyphenols concomitantly enhances antiproliferation and UGT1A1 induction in Caco-2 cells. Life Sci (2011) 0.87
Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J Pharmacol Exp Ther (2002) 0.86
Subadditive withdrawal from cocaine/kappa-opioid agonist combinations in Planaria. Brain Res (2006) 0.85
The dynamic relationship between mu and kappa opioid receptors in body temperature regulation. Life Sci (2005) 0.85
Fixed-dose combinations for emerging treatment of pain. Expert Opin Pharmacother (2012) 0.84
Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis. Catheter Cardiovasc Interv (2009) 0.84
Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection. Antimicrob Agents Chemother (2007) 0.83
Opposing roles of serine/threonine kinases MEKK1 and LOK in regulating the CD28 responsive element in T-cells. Biochem J (2002) 0.83
A quantitative study to assess synergistic interactions between urotensin II and angiotensin II. Eur J Pharmacol (2008) 0.83
A novel role for the immunophilin FKBP52 in copper transport. J Biol Chem (2004) 0.81
Nonlinear isobologram and superadditive withdrawal from cocaine: cannabinoid combinations in planarians. Eur J Pharmacol (2006) 0.81
Polymers for drug eluting stents. Curr Pharm Des (2010) 0.81
Comparison of human and porcine gastric clasp and sling fiber contraction by M2 and M3 muscarinic receptors. Am J Physiol Gastrointest Liver Physiol (2010) 0.80
Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. Eur J Pharmacol (2011) 0.80
On the quantitation of an agonist with dual but opposing components of action: application to vascular endothelial relaxation. Eur J Pharmacol (2011) 0.80
Methylphenidate and impulsivity: a comparison of effects of methylphenidate enantiomers on delay discounting in rats. Psychopharmacology (Berl) (2013) 0.79
Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. J Pharmacol Exp Ther (2013) 0.79
Changes in aorta alpha1-adrenoceptor number and affinity during one year of streptozotocin-induced diabetes in rats. Pharmacology (2005) 0.78
Chemo fog: cancer chemotherapy-related cognitive impairment. Preface. Adv Exp Med Biol (2010) 0.77
Agmatine and a cannabinoid agonist, WIN 55212-2, interact to produce a hypothermic synergy. Eur J Pharmacol (2006) 0.77
Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Behav Pharmacol (2015) 0.77
Baclofen and NOS inhibitors interact to evoke synergistic hypothermia in rats. Life Sci (2005) 0.76
Schild (apparent pA2) analysis of a kappa-opioid antagonist in Planaria. Eur J Pharmacol (2006) 0.76
Pronounced hypothermic synergy between systemic baclofen and NOS inhibitor. Eur J Pharmacol (2004) 0.76
Combining opioid and adrenergic mechanisms for chronic pain. Postgrad Med (2014) 0.76
Inhibitors of unactivated p38 MAP kinase. Bioorg Med Chem Lett (2006) 0.75
Cocaine synergism with α agonists in rat aorta: computational analysis reveals an action beyond reuptake inhibition. Drug Alcohol Depend (2012) 0.75
Modified 'Joyce model' of opioid dependence/withdrawal. Eur J Pharmacol (2006) 0.75
Microstructure and drug-release studies of sirolimus-containing poly(lactide-co-glycolide) films. J Biomed Mater Res B Appl Biomater (2011) 0.75
Tranilast: a pharmaceutical candidate for reduction of adhesions using a novel approach. Semin Reprod Med (2008) 0.75
A nonelutable low-molecular weight heparin stent coating for improved thromboresistance. J Biomed Mater Res B Appl Biomater (2012) 0.75
Morphological and degradation studies of sirolimus-containing poly(lactide-co-glycolide) discs. J Biomed Mater Res B Appl Biomater (2011) 0.75
Lipoxygenase and prostaglandin G/H synthase cascades in cardiovascular disease. Expert Rev Clin Immunol (2006) 0.75
Morphine potentiates dextromethorphan-induced vasodilation in rat superior mesenteric artery. Eur J Pharmacol (2004) 0.75
Future directions. Adv Exp Med Biol (2010) 0.75
Control of cilostazol release kinetics and direction from a stent using a reservoir-based design. J Biomed Mater Res B Appl Biomater (2012) 0.75